Cantor Fitzgerald analyst Alethia Young initiated coverage of Stemline Therapeutics with an Overweight rating and $18 price target. The stock closed Monday up 28c to $10.77. Elzonris could be a "pipeline in a product" for Stemline, which is underappreciated by investors, Young tells investors in a research note. Stemline has a current market capitalization of $520M, and the analyst expects sales from Elzonris for blastic plasmacytoid dendritic cell neoplasm, excluding maintenance therapy, in the U.S. alone to be over $150M by 2025. In addition, Young thinks the potential expansion of Elzonris into the BPDCN maintenance setting in 2021 could produce unadjusted peak U.S. sales of $223M in 2029. She sees upside in the shares over the next 12 months "as investors take notice of progress in the label expansion opportunities."